TD Cowen lowered the firm’s price target on Gilead to $85 from $90 and keeps a Buy rating on the shares. The firm said the 5% product sales beat was led by Veklury with an assist from the liver disease franchise and HIV, while legacy HCV cell therapy and Trodelvy partially offset.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Options Volatility and Implied Earnings Moves Today, April 25, 2024
- Gilead upgraded to Hold from Reduce at HSBC
- Gilead Sciences (GILD) Q1 Earnings Cheat Sheet
- Gilead price target lowered to $75 from $78 at Cantor Fitzgerald
- Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
